Review





Similar Products

94
Developmental Studies Hybridoma Bank motor neuron
Motor Neuron, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/motor neuron/product/Developmental Studies Hybridoma Bank
Average 94 stars, based on 1 article reviews
motor neuron - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
iXCells Biotechnologies human mns
Human Mns, supplied by iXCells Biotechnologies, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human mns/product/iXCells Biotechnologies
Average 94 stars, based on 1 article reviews
human mns - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Axol Bioscience axocells human ipsc derived motor neurons cat
Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of <t>axoCells</t> Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.
Axocells Human Ipsc Derived Motor Neurons Cat, supplied by Axol Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/axocells human ipsc derived motor neurons cat/product/Axol Bioscience
Average 93 stars, based on 1 article reviews
axocells human ipsc derived motor neurons cat - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
iCell Gene Therapeutics icell motor neurons
Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of <t>axoCells</t> Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.
Icell Motor Neurons, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/icell motor neurons/product/iCell Gene Therapeutics
Average 90 stars, based on 1 article reviews
icell motor neurons - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Creative BioMart recombinant human survival motor neuron (smn1) protein
Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of <t>axoCells</t> Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.
Recombinant Human Survival Motor Neuron (Smn1) Protein, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human survival motor neuron (smn1) protein/product/Creative BioMart
Average 90 stars, based on 1 article reviews
recombinant human survival motor neuron (smn1) protein - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemdiff motor neuron maturation kit
Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of <t>axoCells</t> Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.
Stemdiff Motor Neuron Maturation Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stemdiff motor neuron maturation kit/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
stemdiff motor neuron maturation kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Cedarlane mouse motor neuron-like hybrid cell line nsc-34
Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of <t>axoCells</t> Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.
Mouse Motor Neuron Like Hybrid Cell Line Nsc 34, supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse motor neuron-like hybrid cell line nsc-34/product/Cedarlane
Average 90 stars, based on 1 article reviews
mouse motor neuron-like hybrid cell line nsc-34 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemdiff motor neuron differentiation kit
Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of <t>axoCells</t> Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.
Stemdiff Motor Neuron Differentiation Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stemdiff motor neuron differentiation kit/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
stemdiff motor neuron differentiation kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Fujimori Kogyo ipsc-derived motor neurons
Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of <t>axoCells</t> Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.
Ipsc Derived Motor Neurons, supplied by Fujimori Kogyo, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ipsc-derived motor neurons/product/Fujimori Kogyo
Average 90 stars, based on 1 article reviews
ipsc-derived motor neurons - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of axoCells Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.

Journal: Journal of Neurochemistry

Article Title: Neuronal Damage Induced by Gradual Oxidative Stress in i PSC ‐Derived Neurons: Implications for Ferroptosis Involvement and ALS Drug Evaluation

doi: 10.1111/jnc.70246

Figure Lengend Snippet: Protection of neurons from oxidative stress‐induced damage by ferroptosis inhibitors. (a–h) Time course changes in the total neurite length (mm/mm 2 ) of motor neurons (iCell Motor neurons) cultured in DMEM/F12 with antioxidants (+AO) or without antioxidants (−AO). Z‐VAD‐FMK, necrostatin‐1, necrosulfonamide, ferrostatin‐1, liproxstatin‐1, UAMC‐3203, RIPA‐56, or GSK‐872 was added under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Each experiment consists of six wells for the −AO and +AO groups, and two wells for compound treatment. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test. # p = 0.0061, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. * p < 0.0001, Z‐VAD‐FMK at 20 μmol/L; p < 0.0001, necrostatin‐1 at 2.2 and 20 μmol/L; p < 0.0001, ferrostatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, liproxstatin‐1 at 0.11 and 1.0 μmol/L; p < 0.0001, UAMC‐3203 at 0.012, 0.11, and 1.0 μmol/L. See Tables and for detailed statistical analysis. Note that these compound assays were conducted using the same plate sets, but the results are presented in separate graphs for clarity. Therefore, panels a–h share the same control data (+AO and −AO). (i) Time course of changes in the total neurite length (mm/mm 2 ) of motor neurons cultured in +AO, −AO, or with deferoxamine under the −AO condition. The lines represent the average of three experiments with independent cell culture preparations. Error bars indicate SEM. Significant effects increasing AUC and H50 are indicated by # and *, respectively, as determined using two‐way ANOVA followed by Dunnett's multiple comparison test (# and * P < 0.0001 at 5.0 μmol/L). See Tables and for detailed statistical analysis. DMSO at 0.5% was included as the vehicle. (j) Flow cytometry analysis of BODIPY 581/591 C11 oxidation in motor neurons cultured in +AO, −AO, with ferrostatin‐1 (1.0 μmol/L) or AY 9944 (0.1 μmol/L) under the −AO condition for 5 days. (k) Representative images at 168 h of iCell Motor neurons and 312 h of axoCells Human iPSC‐Derived Motor Neurons cultured in DMEM/F12 with (+AO) or without AO (−AO), or with ferrostatin‐1 (1.0 μmol/L) under the −AO condition. Scale bar: 100 μm.

Article Snippet: Human iPSC‐derived motor neurons were purchased from FUJIFILM Cellular Dynamics (iCell Motor Neurons‐01279, cat. no. C1048) and Axol Bioscience (axoCells Human iPSC‐Derived Motor Neurons, cat. no. AX0078). iCell Motor neurons were primarily used as motor neurons, unless otherwise specified.

Techniques: Cell Culture, Comparison, Control, Flow Cytometry, Derivative Assay